Post-approval safety studies: why they matter
Intravitreal therapies are invaluable for treating diabetic macular oedema (DMO). Often clinical trials do not provide sufficiently large patient populations to assess specific safety concerns, hence the need for post-authorisation safety studies, as shown with long-acting corticosteroids.
